Biofrontera Inc. BFRI 深 沪
等待开盘 11-03 09:30:00 美东时间
1.10
+0.030
+2.80%
华盛通- 最 高1.15
- 今 开1.0501
- 成交量 15.91万股
- 最 低 1.05
- 昨 收 1.07
- 总市值 1173.52万
- 52周最高 1.87
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.536
- 委 比 2.75%
- 总股本 1066.84万
- 历史最高 292.60
- 量 比 1.11
- 振 幅 9.35%
- 历史最低 0.536
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biofrontera Finalizes U.S. Rights Acquisition Deal
Biofrontera ( ($BFRI) ) has shared an update. On October 20, 2025, Biofrontera ...
10-25 05:48
Biofrontera Completes Restructuring and Asset Purchase
Biofrontera ( ($BFRI) ) has issued an announcement. On October 23, 2025, Biofro...
10-23 21:21
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
Biofrontera Inc. has acquired full U.S. rights to Ameluz® and RhodoLED® from its former parent company, Biofrontera AG, including the New Drug Application and related patents. The company now pays an earnout of 12%-15% of U.S. net sales, reducing costs previously set at 25%-35%. The transaction was funded by an $11 million investment, with $2.5 million released upon closing, aiming to help the company achieve profitability. The restructuring was ...
10-23 12:45
Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Biofrontera Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, with a webcast presentation at 1:15 p.m. ET. The presentation will discuss the Company's dermatological products, including Ameluz® and RhodoLED® for photodynamic therapy. Management will also host one-on-one meetings with investors. For details, visit the conference website or contact Lytham Partners.
09-26 13:15
Biofrontera AG Announces Significant Impairment Losses
Biofrontera ( ($DE:B8FK) ) has shared an announcement. Biofrontera AG has annou...
09-25 05:27
Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
Biofrontera Inc. has appointed Lytham Partners to lead its investor relations program, aiming to expand its investor base and enhance market recognition. With significant progress, including restructuring, IP acquisition, manufacturing control, and $11 million funding, Biofrontera is positioned for profitability. Lytham Partners, renowned for its investor network and communication platforms, will assist in promoting Biofrontera's growth and value...
09-23 13:20
Biofrontera Completes Treatment Phase In Phase 3 Trial Of Ameluz For Actinic Keratosis On Body; Supplemental New Drug Application Planned For Submission In Q2 2026
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to
09-16 22:32
Biofrontera shares are trading higher after the company announced that the final patient in its Phase 2b clinical trial evaluating Ameluz for the treatment of moderate to severe acne vulgaris completed participation. The company expects to receive top-line data in Q1 2026 and will present findings to the FDA in Q3 2026 as the basis for a future Phase III program.
Biofrontera shares are trading higher after the company announced that the fina...
08-25 20:29
Biofrontera Q2 EPS $(0.57) Misses $(0.42) Estimate, Sales $9.03M Beat $8.30M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42) by 35.71 percent. This is a 1040 percent decrease over losses of $(0.05) per share from the
08-14 05:21
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
